Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Press Releases

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023
Read More »

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023
Read More »

InMed to Participate in Upcoming Investor Events

March 6, 2023
Read More »

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023
Read More »

InMed Submits Form 12b-25

February 9, 2023
Read More »

InMed Provides Business Update and Milestones for 2023

January 10, 2023
Read More »

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022
Read More »

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

December 12, 2022
Read More »

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

November 21, 2022
Read More »

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

November 18, 2022
Read More »

InMed Provides Update on Management Changes

November 17, 2022
Read More »

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

November 16, 2022
Read More »

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

November 11, 2022
Read More »

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

November 10, 2022
Read More »

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

October 26, 2022
Read More »

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

September 23, 2022
Read More »

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

September 19, 2022
Read More »

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

September 13, 2022
Read More »

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

September 9, 2022
Read More »

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

September 8, 2022
Read More »
« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent